Advance Publication

Bioscience of Microbiota, Food and Health

Received: March 22, 2021

Accepted: July 19, 2021

J-STAGE Advance Published Date: August 10, 2021

Effects of the intake of non-live *Bifidobacterium bifidum* on the faecal IgA of full-term infants: a double-blind, randomised, placebo-controlled study

Masaki TERAHARA^{1*}, Yoshitaka NAKAMURA², Misato TSUBOI², Shinji JINNO², Takamitsu TSUKAHARA³, Takao MIYAKE⁴ and Naoki SHIMOJO⁵

¹ R&D Management Department, Meiji Co., Ltd., 1-29-1 Nanakuni, Hachioji, Tokyo 192-0919, Japan

² Food Microbiology and Function Research Laboratories, Meiji Co., Ltd., 1-29-1 Nanakuni, Hachioji, Tokyo 192-0919, Japan

³ Kyoto Institute of Nutrition & Pathology Inc., 7-2 Furuiketani, Tachikawa, Ujitawara, Tsuzuki-gun, Kyoto 610-0231, Japan

⁴ Miyake Women's Clinic, 1-18-5 Oyuminochuo, Midori-ku, Chiba-shi, Chiba 266-0032, Japan

⁵ Center for Preventive Medical Sciences, Chiba University, Yayoicho, 1-33 Inage-ku, Chiba-shi, Chiba 263-8522, Japan

* Corresponding Author: Masaki Terahara (E-mail: masaki.terahara@meiji.com)

Running Head: Non-live *Bifidobacterium* enhanced faecal IgA in term infants

Key words: newborn, infant formula, breastfeeding, probiotics

Abstract

Bifidobacterium bifidum OLB6378 (OLB6378) was selected as a strain that enhances the production of secretory immunoglobulin A (IgA) *in vitro*. This ability of non-live OLB6378 has been shown by a clinical trial in preterm infants. In the present study, we examined whether non-live OLB6378 also enhances the production of secretory IgA, even in full-term infants. One hundred full-term infants were allocated to receive formula with (BbF group, 49 infants) or without non-live OLB6378 (PF group, 51 infants). Breastfeeding was prioritised, so infant formula was used for infants with breastfeeding difficulties. The intervention was initiated by five days of age. The faecal IgA concentration and OLB6378 level were determined at one, two, four, and eight weeks of age. Faecal IgA in the BbF group (1.04 ± 0.47 mg/g of faeces, $n = 45$) was significantly higher than that in the PF group (0.85 ± 0.42 mg/g of faeces, $n = 49$) at four weeks of age ($p = 0.047$). OLB6378 was not detected in faeces at any age. This indicated that production of secretory IgA in full-term infants may also be enhanced by non-live OLB6378 intake.

Introduction

Non-live *Bifidobacterium* is a safer and more convenient food material than live *Bifidobacterium*. Moreover, non-live *Bifidobacterium* cells stimulate the gut immune system *in vitro* and *in vivo* [1, 2]. However, those effects have not been studied sufficiently in a clinical setting,

especially in infants. We selected *Bifidobacterium bifidum* OLB6378 (OLB6378), which enhances the production of secretory immunoglobulin A (IgA) [3], and confirmed the effect of non-live OLB6378 on enhancement of faecal IgA in low-birth-weight infants [4]. From the standpoint of trying to extend the versatility of non-live OLB6378, we hypothesised that non-live OLB6378 enhances the production of secretory IgA, even in full-term infants.

However, the effect observed in low-birth-weight infants may not be observed in full-term infants. Preterm infants have lower body weights, heights, head circumferences, muscle and fat cross-sectional areas, and bone mineral densities than term-born infants [5]. With regard to nutrient digestion and absorption, premature infants do not have levels of intestinal lactase activity and gastric protein digestion capacities comparable to those of mature infants [6-8]. They also have immature immune systems and higher levels of intestinal permeability than term infants [9, 10]. Moreover, low birth weight is negatively associated with exclusive breastfeeding [11]. Given these differences between preterm and full-term infants, we considered that the effects of non-live OLB6378 should be demonstrated again in full-term infants.

As a pilot study, we evaluated the effects of non-live OLB6378 administration on the enhancement of faecal IgA in full-term infants in this study.

Materials and Methods

Study Design and Ethical Approval

This was a double-blind, randomised, placebo-controlled study conducted among 100 newborn infants and their mothers. The protocol was approved by the Ethics Committee of Chiba University (Chiba, Japan; registration No. 2941) in compliance with the Declaration of Helsinki (June 2018). This study was registered in the University Hospital Medical Information Network (UMIN) Clinical Trial Registry (UMIN000033295).

Participants

Participants were recruited from pairs of infants (37–42 weeks of gestation; birthweight of 2,500 to 4,000 g) and their mothers at Miyake Women's Clinic (Chiba, Japan) between October 2018 and March 2019. Written informed consent was obtained from each infant's mother before enrolment in this study. The exclusion criteria were the presence of serious infections and major congenital malformations.

Randomisation and Blinding

After pairs of infants and their mothers were enrolled, they were automatically randomised and divided into two groups, namely, the BbF group (infant formula containing non-live OLB6378) and PF group (placebo infant formula), by using the web system of Soiken Co., Ltd. (Tokyo, Japan)

and minimisation for sex and delivery method. All subject data were anonymised, and the group allocations were concealed by Soiken Co., Ltd. The infant formula containing non-live OLB6378 and the placebo infant formula (blinded) were provided by Meiji Co., Ltd. (Tokyo, Japan), and the intervention was concealed by Meiji Co., Ltd.

Interventions and Procedure

Breastfeeding was prioritised, and infant formula was used for infants when breastfeeding was impossible or when the amount of breast milk was insufficient. The intervention was initiated by five days of age and continued until two months of age. The test infant formula was prepared in the same manner as the placebo infant formula, which was commercially available. Briefly, 13.5 g of powdered formula was fully dissolved in a bottle by adding approximately 65 mL of cooled boiled water (above 70°C). The volume was then adjusted to 100 mL with cooled boiled water, and the entire bottle of formula was cooled until it was less than 40°C. Infants in the PF group received the Meiji Hohoemi infant formula (Meiji Co., Ltd., Tokyo, Japan) as a placebo, whereas those in the BbF group received the test infant formula, which was comprised of Meiji Hohoemi infant formula with a small amount of lactose replaced with non-live OLB6378 powder (37 mg of non-live OLB6378 concentrate containing $> 9.3 \times 10^9$ non-live cells per 100 g powdered infant formula). The amount of non-live OLB6378 (10 mg) in 200 mL of the infant formula was the same as that

administered to low-birth-weight infants [4]. Non-live OLB6378 was prepared by heating (at 80°C for more than 5 min) a concentrated culture of *B. bifidum* OLB6378, which was cultivated using a hydrolysed milk protein medium. The stools of the infants were collected, and faecal IgA and *Bifidobacterium* were measured at one, two, four, and eight weeks of age. The amount of formula intake was recorded for three days before the stool was sampled. Breast milk samples were collected at two, four, and eight weeks of the infant's age. The samples were stored at –20°C for several days immediately after sampling and then at –80°C until use.

Quantitative Analyses of IgA

The quantification of faecal IgA was performed as described previously [4]. Breast milk was centrifuged ($9,100 \times g$, 10 min, 4°C), and the whey in it was used for the quantification of IgA using a commercial ELISA kit (Human IgA ELISA Quantitation Set, Bethyl Laboratories, Inc., Montgomery, TX, USA).

Quantitative Analyses of Bifidobacterium

For the quantification of *Bifidobacterium*, a real-time polymerase chain reaction (PCR) was performed with *Bifidobacterium* genus-specific primers, as described previously [12, 13]. *B. bifidum* OLB6378 was quantified using real-time PCR with strain-specific primers [14]. For the

real-time PCR assay, bacterial genomic DNA was extracted from the stool samples using a commercial extraction kit (QuickGene DNA tissue kit, Kurabo, Osaka, Japan) as described previously [12, 15]. The detection limits of *Bifidobacterium* and *B. bifidum* OLB6378 were 10^4 and 10^7 cells/g of faeces, respectively.

Outcome Measures

The primary outcome was defined as the concentration of faecal IgA. A previous study showed that the faecal IgA concentrations of preterm infants who received non-live OLB6378 were higher at one and two months of age [4]. Similarly, in this study, the faecal IgA levels at four and eight weeks of age were the focus of attention. The secondary outcome was defined as the amount of faecal *Bifidobacterium*.

In addition, exploratory subgroup analyses were performed. Infants were divided into the following three subgroups on the basis of the volume of infant formula intake recorded during the trial period: (1) always < 200 mL/day (LM subgroup), (2) always ≥ 200 mL/day (HM subgroup), and (3) others (not always < 200 mL/day or > 200 mL/day; MM subgroup). In each subgroup, the PF and BbF groups were compared with exclusively breastfeeding infants ($n = 6$), who were excluded from the primary outcome analyses in this study.

Sample Size Calculation

Whitehead *et al.* recommended using pilot trial sample sizes of 75, 25, 15, and 10 per treatment arm for standardised effect sizes that are extra small (≤ 0.1), small (0.2), medium (0.5), or large, respectively [16]. If the effect size of the faecal IgA of full-term infants was too small, it would be difficult to determine whether the intake of non-live OLB6378 had an effect on faecal IgA in full-term infants. Therefore, we aimed to include 30 infants in each group. To allow for up to 20% attrition and 20% exclusion, 100 infants were enrolled in this study (50 per group).

Statistical Analyses

The data of exclusively breastfed infants were excluded from the outcome analyses. Between-group statistical significance for the faecal IgA concentration was determined using Student's *t*-test and the Brunner–Munzel test. Between-group statistical significance for the faecal *Bifidobacterium* detection rate and cell counts was determined using Fisher's exact test and the Mann–Whitney U-test. For all analyses, a *p*-value < 0.05 was considered statistically significant.

Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA) or R version 2.13 (The R Foundation, Vienna, Austria) for primary and secondary outcomes. Subgroup analyses and linear regression analysis were performed using IBM SPSS Statistics version 27 (IBM Corp., Armonk, NY, USA).

Results

Background Characteristics

Following the protocol, 100 pairs of newborn infants and mothers were enrolled and randomly assigned to the PF group (n = 51) or BbF group (n = 49). During the recruitment period, 258 full-term infants were born in the clinic, and 39% of them were enrolled after obtaining informed consent from their mothers. The full analyses set (n = 49 for the PF group; n = 45 for the BbF group) was defined after excluding six infants who were exclusively breastfed (Figure 1). Two infants in the BbF group discontinued participation in the study owing to a respiratory syncytial virus infection (18 and 33 days of age).

In terms of the characteristics of the study population, gestational age was greater in the BbF group than in the PF group (Table 1). There were no significant differences in the other background characteristics. There were no side effects in either group in this study. There was no difference in adverse events between the two groups.

Outcomes

The faecal IgA concentration in the BbF group was significantly higher than that in the PF group at four weeks of age according to the *t*-test (Figure 2). Linear regression after adjusting for

gestational age and mother's age revealed a significant partial correlation coefficient between the groups' faecal IgA levels at four weeks of age (Table 2).

In this study, *B. bifidum* OLB6378 was not detected in any infant faeces. The frequency of *Bifidobacterium* detection was higher in the BbF group than in the PF group at one, two, and four weeks of age, with the values tending to be higher at eight weeks of age (Table 3). However, no significant difference was observed in *Bifidobacterium* counts calculated from *Bifidobacterium*-positive samples.

Effects of Breastfeeding (Bottle Feeding)

No difference in the IgA concentration of breast milk was observed between the PF and BbF groups (Table 4). A negative correlation between bottle feeding and faecal IgA was observed until two weeks of age (Figure 3).

Subgroup analyses

In the HM subgroup (low breastfeeding rate and high non-live OLB6378 intake subgroup), the exploratory subgroup analyses revealed that the faecal IgA levels in the PF group were lower than those of exclusively breastfed infants until four weeks of age (Figure 4). In contrast, a difference was not observed between the BbF group and exclusively breastfed infants.

Discussion

In this randomised study, the faecal IgA concentration in the BbF group was significantly higher than that in the PF group at four weeks of age. Additionally, OLB6378 was not detected in faeces at any age. These results showed that intake of non-live OLB6378 potentially enhance faecal IgA in full-term infants. This is the first clinical study suggesting the effects of non-live *Bifidobacterium* on enhancement of secretory IgA in full-term infants, similar to the results in preterm infants [4].

For the evaluation of faecal IgA in the infants, it was necessary to consider the IgA from breast milk because breastfeeding was ethically prioritised during this study. In fact, the difference in the faecal IgA level at four weeks of age between the BbF and PF groups was not so large (1.04 mg/g vs 0.85 mg/g). In addition, the faecal IgA level of the PF group at four weeks of age (0.85 mg/g) appeared to be lower than those at one (0.97 mg/g), two (0.90 mg/g), and eight (0.91 mg/g) weeks of age. This was possibly caused by IgA from breast milk because most of the infants were fed breast milk. Moreover, intake of non-live OLB6378 depends on the amount of bottle feeding, which is inversely proportional to the amount of breastfeeding, and this makes the discussion of this issue complicated. Maruyama *et al.* demonstrated that the faecal IgA level rapidly increased after the intake of colostrum [17]. Furthermore, Maruyama speculated that the intestinal IgA level was

markedly influenced by the intake of breast milk. In the current study, we also found a negative correlation between formula intake and faecal IgA at one and two weeks of age but not at four and eight weeks of age. This was most likely caused by the IgA concentration in the breast milk being high. The negative correlation can be explained by the high IgA concentration of the colostrum and the gradual decline in the concentration until 15 days of age [18].

Furthermore, considering the effect of the IgA in breast milk on the level of faecal IgA, we performed a subgroup analysis. Infants were divided on the basis of the volume of bottle feeding during this study. In this subgroup analysis, infants were simultaneously divided based on the amount of non-live OLB6378 ingested because the intake of non-live OLB6378 was dependent on the volume of bottle feeding. The faecal IgA level of the PF group in the HM subgroup (low breastfeeding rate and high non-live OLB6378 intake subgroup) was lower than that of the exclusively breastfed infants until four weeks of age, although no difference was observed in the LM subgroup (high breastfeeding rate and low non-live OLB6378 intake subgroup; Figure 4). The impact of breast milk on the faecal IgA level was smaller in the HM subgroup than in the LM subgroup. In the HM subgroup, the faecal IgA level in the BbF group at four weeks of age was similar to that of the exclusively breastfed infants. In contrast, the faecal IgA in the PF group remained at a low level at four weeks of age. Koutras also showed that the faecal IgA of exclusively formula-fed infants remained completely undetectable in all neonates at two weeks of age, mostly

undetectable or at very low levels at four weeks of age, and at very low levels at eight weeks of age [19]. In the same way, the faecal IgA levels might have been lower in the HM subgroup until four weeks of age. Therefore, at four weeks of age, the effects of non-live OLB6378 on the upregulation of pIgR and IgA production [3, 20] might have been observed in the HM subgroup. This suggested the possibility that the faecal IgA levels could have reached the levels of exclusive breastfeeding earlier in the BbF group than in the PF group.

This result was also supported by the linear regression analysis, which showed significant linear correlation between the intervention and increased IgA at four weeks of age. The analysis also showed that maternal age also independently affected the faecal IgA level. Several reports have suggested that older maternal age may be beneficial for early child health [21-23]. The social advantage associated with an older maternal age was considered one possible factor responsible for this [21, 22]. The present study might also suggest that older maternal age could possibly be a factor involved in the immunological development of infants.

The results of this study showed no side effects. Although there were two serious adverse events in the BbF group caused by respiratory syncytial virus (RSV)-related hospitalisation, there was no evidence of any causal relationship related to the intake of the non-live OLB6378. Very young infants, especially those six months old and younger, are at greatest risk for severe illness caused by RSV, so those infants were hospitalised. Both of these infants in the BbF group were

discharged without any sequelae. With regard to live *Bifidobacterium*, several reports have shown that probiotic supplementation increased the cell counts of *Bifidobacterium* and amount of IgA in faeces [24-26]. However, it has also been reported that probiotic-supplemented infants had higher incidences of mucosal-associated illnesses in the first two years of life [27]. Moreover, *Bifidobacterium* bacteraemia and meningitis have been reported [28, 29], and the possibility of side effects caused by probiotic strains has also been reported in preterm infants [30]. Unlike live probiotics, non-live probiotics do not cause pathological conditions on their own, even though they stimulate the gastrointestinal immune system [31, 32]. Even non-live probiotics have reportedly enhanced the production of IgA in Peyer's patch cells *in vitro* [33], in mice and post-weaning piglets *in vivo* [34, 35], and in preschool children in clinical trials [36]. Nevertheless, only one clinical trial using infant formula containing non-live *Bifidobacterium* has been conducted. Faecal IgA was also increased in preterm infants who consumed fermented formula, the manufacturing process of which includes a fermentation step with two probiotic strains, namely *B. breve* C50 and *Streptococcus thermophilus* 065, inactivated by heat at the end of the process [37]. This result was similar to that of our previous study on preterm infants who were administered non-live OLB6378 [9] and also supports the results of the present study.

Regarding the secondary outcome of this study, the detection rate of faecal

Bifidobacterium (%) in the BbF group was higher than that in the PF group, even though non-live

OLB6378 was administered to full-term infants in the BbF group (Table 3). Tsuji *et al.* reported that the detection rate of intestinal *Bifidobacterium* in healthy Japanese infants was 73% at seven days of age and 88% at one month of age [38]. In contrast, Sakata *et al.* and Penders *et al.* reported that the detection rate of *Bifidobacterium* was 100% at one month of age [39, 40]. The *Bifidobacterium* detection rate in this study was similar to that reported by Tsuji *et al* [38] and that of the preterm infants that we reported previously (approximately 84% at four weeks of age). The *Bifidobacterium* detection rate could have appeared to be higher in the BbF group than in the PF group in this study because the detection rates were themselves objectively low. Unfortunately, we cannot explain why non-live OLB6378 intake increased the *Bifidobacterium* detection rate. Regarding this point, the effect of heat-killed *Bifidobacterium longum* BR-108 on mouse caecal microbiota is similar to that of viable BR-108, most likely because both heat-killed and viable BR-108 stimulate the gut immune system in similar manners [2]. We can only speculate that the *Bifidobacterium* detected in faeces was not the OLB6378 strain because the *Bifidobacterium* levels in the faeces (almost all were $> 10^8$ cells/g of faeces) were higher than the detection limit for the OLB6378 strain (10^7 cells/g of faeces). Therefore, at minimum, the non-live cells of OLB6378 did not influence or only slightly influenced the numbers of *Bifidobacterium* in the faeces.

This study had some limitations. First, there was a difference in gestational age between the groups. However, it has been reported that there is a steady rise in the level of salivary IgA from

birth to 18 months in both preterm and full-term children, with no significant difference between them [41]. Moreover, after adjusting for gestational and maternal ages, the linear regression analysis revealed a significant partial correlation coefficient between groups' faecal IgA levels at four weeks of age (Table 2). Second, we did not investigate colostrum feeding. Therefore, the effects of colostrum on faecal IgA were not clear in this study. Finally, a power of 0.51 was insufficient for the faecal IgA at four weeks of age in this study ($p = 0.047$, Cohen's $d = 0.43$). Therefore, a randomised study, in which the sample size is determined on the basis of the effect size of this pilot study, is needed in the future.

In conclusion, our results showed that the amount of intestinal IgA in full-term infants was increased by feeding them infant formula containing non-live OLB6378. Intake of non-live *Bifidobacterium* may stimulate IgA production in not only preterm infants but also full-term infants.

Conflict of Interest and Funding Disclosure

Authors M. Terahara, Y. Nakamura, M. Tsuboi, and S. Jinno are employees of Meiji Co. Ltd., Tokyo, Japan. The other authors declare that they are free of any conflicts of interest. This study was funded by Meiji Co. Ltd., Tokyo.

Acknowledgements

We would like to thank all the infants and parents who participated in this study. We would also like to thank the staff at Miyake Women's Clinic and Soiken Co., Ltd.

References

1. Yasui H, Nagaoka N, Mike A, Hayakawa K, Ohwaki M. 1992. Detection of *Bifidobacterium* Strains that Induce Large Quantities of IgA. *Microb Ecol Health Dis.* 5: 155–162.
2. Makioka Y, Tsukahara T, Ijichi T, Inoue R. 2018. Oral supplementation of *Bifidobacterium longum* strain BR-108 alters cecal microbiota by stimulating gut immune system in mice irrespectively of viability. *Biosci Biotechnol Biochem* 82: 1180-1187.
3. Terahara M. 2017. Challenge of development of probiotics for neonates (In Japanese). *Milk Science* 66: 247–253.
4. Tanaka K, Tsukahara T, Yanagi T, Nakahara S, Furukawa O, Tsutsui H, Koshida S. 2017. *Bifidobacterium bifidum* OLB6378 simultaneously enhances systemic and mucosal humoral immunity in low birth weight infants: a non-randomized study. *Nutrients* 9: 195. Available at: <https://www.mdpi.com/2072-6643/9/3/195>
5. Ahmad I, Nemet D, Eliakim A, Koeppel R, Grochow D, Coussens M, Gallitto S, Rich J, Pontello A, Leu SY, Cooper DM, Waffarn F. 2010. Body composition and its components in preterm and term newborns: a cross-sectional, multimodal investigation. *Am J Hum Biol* 22: 69–75.

6. Mobassaleh M, Montgomery RK, Biller JA, Grand RJ. 1985. Development of carbohydrate absorption in the fetus and neonate. *Pediatrics* 75: 160–166.
7. Kien CL, Heitlinger LA, Li BU, Murray RD. 1989. Digestion, absorption, and fermentation of carbohydrates. *Semin Perinatol* 13: 78–87.
8. Demers-Mathieu V, Qu Y, Underwood MA, Borghese R, Dallas DC. 2018. Premature infants have lower gastric digestion capacity for human milk proteins than term infants. *J Pediatr Gastroenterol Nutr* 66: 816–821.
9. Melville JM, Moss TJM, 2013. The immune consequences of preterm birth. *Front Neurosci* 7: 79. Available at: <https://www.frontiersin.org/articles/10.3389/fnins.2013.00079/full>
10. Weaver LT, Laker MF, Nelson R, 1984. Intestinal permeability in the newborn. *Arch Dis Child* 59: 236–241.
11. Kaneko A, Kaneita Y, Yokoyama E, Miyake T, Harano S, Suzuki K, Ibuka E, Tsutsui, T, Yamamoto Y, Ohida T. 2006. Factors associated with exclusive breast-feeding in Japan: for activities to support child-rearing with breast-feeding. *J Epidemiol* 16: 57–63.
12. Tanaka K, Nakamura Y, Terahara M, Yanagi T, Nakahara S, Furukawa O, Tsutsui H, Inoue R, Tsukahara T, Koshida S. 2019. Poor Bifidobacterial colonization is associated with late provision of colostrum and improved with probiotic supplementation in low birth weight infants. *Nutrients* 11: 839. Available at: <https://www.mdpi.com/2072-6643/11/4/839>

13. Gueimonde M, Tölkö S, Korpimäki T, Salminen S. 2004. New real-time quantitative PCR procedure for quantification of *Bifidobacteria* in human fecal samples. *Appl Environ Microbiol* 70: 4165–4169.
14. Toshimitsu T, Nakamura M, Ikegami S, Terahara M, Itou, H. 2013. Strain-specific identification of *Bifidobacterium bifidum* OLB6378 by PCR. *Biosci Biotechnol Biochem* 77: 572–576.
15. Tsukahara T, Inoue R, Nakayama K, Inatomi T, 2018. Inclusion of *Bacillus amyloliquefaciens* strain TOA5001 in the diet of broilers suppresses the symptoms of coccidiosis by modulating intestinal microbiota. *Anim Sci J* 89: 679–687.
16. Whitehead AL, Julious SA, Cooper CL, Campbell MJ. 2016. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. *Stat Methods Med Res* 25: 1057–1073.
17. Maruyama K, Hida M, Kohgo T, Fukunaga Y. 2009. Changes in salivary and fecal secretory IgA in infants under different feeding regimens. *Pediatr Int* 51: 342–345.
18. Bridgman SL, Konya T, Azad MB, Sears MR, Becker AB, Turvey SE, Mandhane PJ, Subbarao P, Scott JA, Field CJ, Kozyrskyj AL, CHILd Study Investigators. 2016. Infant gut immunity: a preliminary study of IgA associations with breastfeeding. *J Dev Orig Health Dis* 7: 68–72.

19. Koutras AK, Vigorita VJ. 1989. Fecal secretory immunoglobulin A in breast milk versus formula feeding in early infancy. *J Pediatr Gastroenterol Nutr* 9: 58–61.
20. Nakamura Y, Terahara M, Iwamoto T, Yamada K, Asano M, Kakuta S, Iwakura Y, Totsuka M. 2012. Upregulation of polymeric immunoglobulin receptor expression by the heat-inactivated potential probiotic *Bifidobacterium bifidum* OLB6378 in a mouse intestinal explant model. *Scand J Immunol* 75: 176–183.
21. Kato T, Yorifuji T, Yamakawa M, Inoue S, Doi H, Eboshida A, Kawachi I. 2017. Association of maternal age with child health: a Japanese longitudinal study. *PLoS One* 24; 12(2):e0172544. Available at:
<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0172544>
22. Sutcliffe AG, Barnes J, Belsky J, Gardiner J, Melhuish E. 2012. The health and development of children born to older mothers in the United Kingdom: observational study using longitudinal cohort data. *BMJ* 21; 345: e5116. Available at:
<https://www.bmj.com/content/bmj/345/bmj.e5116.full.pdf>
23. Kim YN, Choi DW, Kim DS, Park EC, Kwon JY. 2021. Maternal age and risk of early neonatal mortality: a national cohort study. *Sci Rep* 12; 11:814. Available at:
<https://www.nature.com/articles/s41598-021-80968-4>

24. Radke M, Picaud J-C, Loui A, Cambonie G, Faas D, Lafeber HN, de Groot N, Pecquet SS, Steenhout PG, Hascoet JM. 2017. Starter formula enriched in prebiotics and probiotics ensures normal growth of infants and promotes gut health: a randomized clinical trial. *Pediatr Res* 81: 622–631.
25. Holscher HD, Czerkies LA, Cekola P, Litov R, Benbow M, Santema S, Alexander DD, Perez V, Sun S, Saavedra JM, Tappenden KA. 2012. *Bifidobacterium lactis* Bb12 enhances intestinal antibody response in formula-fed infants: a randomized, double-blind, controlled trial. *JPEN J Parenter Enteral Nutr* 36: 106S–117S.
26. Bazanella M, Maier TV, Clavel T, Lagkouvardos I, Lucio M, Maldonado-Gòmez MX, Autran C, Walter J, Bode L, Schmitt-Kopplin P, Haller D. 2017. Randomized controlled trial on the impact of early-life intervention with bifidobacteria on the healthy infant fecal microbiota and metabolome. *Am J Clin Nutr* 106: 1274–1286.
27. Quin C, Estaki M, Vollman DMJ, Barnett A, Gill SK, Gibson DL. 2018. Probiotic supplementation and associated infant gut microbiome and health: a cautionary retrospective clinical comparison. *Sci Rep* 8: 8283. Available at: <https://www.nature.com/articles/s41598-018-26423-3>
28. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C. 2017. Norwegian Study Group on Invasive Bifidobacterial Infections. *Bifidobacterium* Bacteremia: clinical characteristics and a genomic approach to assess pathogenicity. *J Clin Microbiol* 55: 2234–2248.

29. Nakazawa T, Kaneko K, Takahashi H, Inoue S. 1996. Neonatal meningitis caused by *Bifidobacterium breve*. Brain Dev 18: 160–162.
30. Sato S, Uchida T, Kuwana S, Sasaki K, Watanabe T, Saito J, Kawaji T. 2016. Bacteremia induced by *Bifidobacterium breve* in a newborn with cloacal exstrophy. Pediatr Int 58: 1226–1228.
31. Adams CA. 2010. The probiotic paradox: live and dead cells are biological response modifiers. Nutr Res Rev 23: 37–46.
32. Kawashima T, Ikari N, Kouchi T, Kowatari Y, Kubota Y, Shimojo N, Tsuji NM. 2018. The molecular mechanism for activating IgA production by *Pediococcus acidilactici* K15 and the clinical impact in a randomized trial. Sci Rep 8: 5065. Available at: <https://www.nature.com/articles/s41598-018-23404-4>
33. Kim SH, Jeung W, Choi ID, Jeong JW, Lee DE, Huh CS, Kim GB, Hong SS, Shim JJ, Lee JL, Sim JH, Ahn YT. 2016. Lactic acid bacteria improves Peyer's patch cell-mediated immunoglobulin A and tight-junction expression in a destructed gut microbial environment. J Microbiol Biotechnol 26: 1035–1045.
34. Hiramatsu Y, Hosono A, Takahashi K, Kaminogawa S. 2007. Bifidobacterium components have immunomodulatory characteristics dependent on the method of preparation. Cytotechnology 55: 79–87.

35. Tsuruta T, Ryo I, Takamitsu T, Noritaka M, Masayuki H, Kazunari U. 2009. A cell preparation of *Enterococcus faecalis* strain EC-12 stimulates the luminal immunoglobulin A secretion in juvenile calves. *Anim Sci J* 80: 206–211.
36. Hishiki H, Kawashima T, Tsuji NM, Ikari N, Takemura R, Kido H, Shimojo N. 2020. A double-blind, randomized, placebo-controlled trial of heat-killed *Pediococcus acidilactici* K15 for prevention of respiratory tract infections among preschool children. *Nutrients* 12: 1989. Available at: <https://www.mdpi.com/2072-6643/12/7/1989>
37. Campeotto F, Suau A, Kapel N, Magne F, Viallon V, Ferraris L, Waligora-Dupriet AJ, Soulaines P, Leroux B, Kalach, N, Dupont C, Butel M-J. 2011. A fermented formula in pre-term infants: clinical tolerance, gut microbiota, down-regulation of faecal calprotectin and up-regulation of faecal secretory IgA. *Br J Nutr* 105: 1843–1851.
38. Tsuji H, Oozeer R, Matsuda K, Matsuki T, Ohta T, Nomoto K, Tanaka R, Kawashima M, Kawashima K, Nagata S, Yamashiro Y. 2021. Molecular monitoring of the development of intestinal microbiota in Japanese infants. *Benef Microbes* 3: 113–125.
39. Sakata S, Tonooka T, Ishizeki S, Takada M, Sakamoto M, Fukuyama M, Benno Y. 2005. Culture-independent analysis of fecal microbiota in infants, with special reference to *Bifidobacterium* species. *FEMS Microbiol Lett* 243: 417–423.

40. Penders J, Vink C, Driessen C, London N, Thijs C, Stobberingh EE. 2005. Quantification of *Bifidobacterium* spp., *Escherichia coli* and *Clostridium difficile* in faecal samples of breast-fed and formula-fed infants by real-time PCR. FEMS Microbiol Lett 243: 141–147.
41. Wan AKL, Seow WK, Purdie DM, Bird PS, Walsh LJ, Tudehope DI. 2003. Immunoglobulins in saliva of preterm and full-term infants. Oral Microbiol Immunol 18: 72–78.

Fig. 1. Study flowchart.

PF, placebo infant formula; BbF, infant formula containing non-live *B. bifidum* OLB6378.

Fig. 2. Transition of faecal IgA.

PF, placebo infant formula; BbF, infant formula containing non-live *B. bifidum* OLB6378; E, exclusive breastfeeding; NS, not significant (both Student's *t*-test and Brunner–Munzel test); ^a*p* < 0.05 (*t*-test); ^b*p* < 0.05 (Brunner–Munzel test)

Fig. 3. Relationship between formula intake and faecal IgA.

○, placebo infant formula (PF group); ●, infant formula containing non-live *B. bifidum* OLB6378 (BbF group); ■, Exclusive breastfeeding. The Spearman's rank correlation coefficients (p -value) at one, two, four, and eight weeks of age were -0.28 (< 0.01), -0.38 (< 0.01), -0.13 (0.22), and -0.08 (0.49), respectively.

Fig. 4. Subgroup analyses of faecal IgA.

□, exclusive breastfeeding; ■, placebo infant formula (PF group); ■, infant formula containing non-live *B. bifidum* OLB6378 (BbF group). Different letters indicate significant differences at each age (Tukey test).

Table 1. Characteristics of infants in the PF and BbF groups

	PF group (n = 49)	BbF group (n = 45)	p-value
<i>Maternal characteristics</i>			
Age (years) ¹	31.7 ± 4.9	31.7 ± 5.6	NS ⁴
Parity ¹	0.66 ± 0.77	0.69 ± 0.90	NS ⁴
<i>Infant characteristics</i>			
Gestational age (days) ¹	274.2 ± 5.8	276.6 ± 5.7	0.04 ⁴
Weight at birth (g) ¹	3058.3 ± 335.1	3120.1 ± 319.8	NS ⁴
Height at birth (cm) ¹	48.1 ± 1.7	48.8 ± 1.3	NS ⁴
Head circumference at birth (cm) ¹	32.7 ± 1.4	33.0 ± 1.5	NS ⁴
Apgar score at 1 min ¹	8.6 ± 0.8	8.6 ± 1.3	NS ⁴
Apgar score at 5 min ¹	9.6 ± 0.6	9.5 ± 0.8	NS ⁴
Caesarean section ²	6 (12.2)	5 (11.1)	NS ⁵
Male sex ²	22 (44.9)	20 (44.4)	NS ⁵
<i>Outcomes</i>			
Amount of bottle feeding (mL/day) ³			
One week of age	302 (189, 423)	200 (120, 385)	NS ⁶
Two weeks of age	360 (110, 510)	213 (76, 375)	NS ⁶
Four weeks of age	308 (56, 657)	218 (69, 520)	NS ⁶
Eight weeks of age	207 (0, 722)	117 (43, 510)	NS ⁶
Mortality ²	0 (0)	0 (0)	-
Serious adverse event ²	0 (0)	2 (4.4)	NS ⁵

PF, placebo infant formula; BbF, infant formula containing non-live *B. bifidum* OLB6378; NS, not significant. ¹Mean ± standard deviation, ²Number (%), ³Median and quartile (Q1, Q3), ⁴Student's *t*-test, ⁵Fisher's exact test. ⁶Mann-Whitney U-test. Serious adverse events included two cases of respiratory syncytial virus infection.

Table 2. Linear regression analysis of factors associated with faecal IgA at four weeks of age

Factors	Univariate		Multivariate	
	PRC (95% CI)	<i>p</i> -value	PRC (95% CI)	<i>p</i> -value
Group (BbF group)	188.3 (2.5, 374.0)	0.047	191.8 (4.1, 379.4)	0.04
Sex (male)	187.4 (1.6, 373.2)	0.048	159.9 (-23.4, 343.3)	NS
Caesarean delivery	168.4 (-129.4, 466.2)	NS	171.9 (-143.6, 487.5)	NS
Gestational age	5.5 (-10.7, 21.8)	NS	0.5 (-15.6, 16.6)	NS
Weight at birth	-0.1 (-0.4, 0.2)	NS	-0.1 (-0.4, 0.2)	NS
Height at birth	35.8 (-23.9, 95.5)	NS	29.5 (-33.0, 91.9)	NS
Head circumference at birth	7.5 (-55.6, 70.7)	NS	3.9 (-52.7, 65.0)	NS
Apgar score at 5 min	12.4 (-128.5, 153.3)	NS	11.3 (-130.8, 153.5)	NS
Maternal age	21.1 (2.8, 39.4)	0.03	21.5 (3.4, 39.6)	0.03
Maternal history of allergy	42.8 (-188.1, 273.8)	NS	-14.7 (-250.6, 221.2)	NS
Parity	74.4 (-39.2, 187.9)	NS	-0.3 (-128.1, 127.5)	NS
Log (<i>Bifidobacterium</i>) at four weeks of age	24.4 (-16.9, 65.7)	NS	20.7 (-20.4, 61.9)	NS
IgA in breast milk at four weeks of age	-0.08 (-0.17, 0.01)	NS	-0.04 (-0.13, 0.06)	NS
Formula intake at four weeks of age	-0.30 (-0.69, 0.03)	NS	-0.22 (-0.54, 0.10)	NS

BbF, infant formula containing non-live *B. bifidum* OLB6378; PRC; partial regression coefficient; CI, confidence interval. The multivariate was adjusted for group, maternal age, and gestational age

Table 3. Prevalence and counts (log₁₀ cells/g of faeces) of *Bifidobacterium*

Age, weeks	Prevalence, n (%)			Counts, median and quartile (Q1, Q3)		
	PF group	BbF group	<i>p</i> -value ¹	PF group	BbF group	<i>p</i> -value ²
1	27 (55.1)	34 (75.6)	0.03	9.14 (8.88, 9.55)	9.12 (8.62, 9.83)	NS
2	29 (59.2)	39 (86.7)	< 0.01	9.21 (8.86, 9.52)	8.94 (8.19, 9.47)	NS
4	32 (65.3)	41 (91.1)	< 0.01	9.42 (8.92, 9.65)	9.14 (8.43, 9.42)	NS
8	41 (83.7)	43 (95.6)	NS	9.17 (8.87, 9.55)	9.15 (8.55, 9.39)	NS

PF, placebo infant formula (n = 49); BbF, infant formula containing non-live *B. bifidum* OLB6378 (n = 45); NS, not significant. Counts, median and quartile (Q1, Q3), were calculated from *Bifidobacterium* -positive samples. ¹Fisher's exact test, ²Mann-Whitney U-test.

Table 4. Median and quartile (Q1, Q3) IgA concentrations (µg/mL) in breast milk

Age, weeks	PF group	BbF group	<i>p</i> -value ¹
2	426 (285, 716)	395 (340, 558)	NS
4	340 (232, 655)	311 (248, 450)	NS
8	270 (186, 381)	265 (195, 383)	NS

PF, placebo infant formula; BbF, infant formula containing non-live *B. bifidum* OLB6378; NS, not sig-nificant. ¹Mann-Whitney U-test.